Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Martin Burton has been appointed as Co-Chair of the Cochrane Governing Board, for an initial term of two years.

Professor Martin Burton

Professor Burton served as a member of the Board, and Treasurer, until this month, and already has substantial leadership experience in Cochrane as Director of Cochrane UK and Co-ordinating Editor of the Cochrane Ear Nose & Throat Disorders Group at the Nuffield Department of Surgical Sciences. He will share chairing duties with Professor Cindy Farquhar, who is Co-ordinating Editor of the Gynaecology and Fertility Group, based in Auckland, New Zealand.

The Board is responsible for overseeing the development and implementation of Cochrane’s strategic direction. It also oversees the work of Cochrane's Chief Executive Officer and Central Executive team, which supports development and delivery of all work across Cochrane groups and projects.

Professor Burton is Professor of Otolaryngology at the University of Oxford, Honorary Consultant Otolaryngologist at Oxford University Hospitals NHS Foundation Trust and Fellow in Clinical Medicine at Balliol College, Oxford.

Dr Bruno Holthof welcomed Professor Burton's appointment saying, 'Martin’s invaluable experience as a past Cochrane Board member and his leadership as Director of Cochrane UK will ensure his co-chairmanship will benefit the Cochrane Community greatly.'

Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health. Cochrane produces systematic reviews which study all of the best available evidence generated through research and make it easier to inform decisions about health. Cochrane is a UK charity with a global reach.  Collaborators from more than 120 countries work together to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest. Cochrane’s work is recognised as representing an international gold standard for high quality, trusted information.

For more information, please contact therese.docherty@cochrane.nhs.uk

Similar stories

Another successful year for SITU NDS

The Surgical Intervention Trials Unit in the Nuffield Department of Surgical Sciences (SITU NDS) has had another successful year, now running ten randomised controlled trials across surgical specialties and securing a total of £32 million in current peer-reviewed grants.

NDS projects awarded CRUK Oxford Cancer Development Fund

Two research projects at the Nuffield Department of Surgical Sciences (NDS) have been awarded pump-prime funding from this year’s CRUK Oxford Centre Development Fund.

DPhil student awarded prestigious prize by Italian medical academy

This year’s winner of the prestigious Giovanni Maria Lancisi Award is Dr Pierfrancesco Lapolla Losasso, DPhil candidate at Nuffield Department of Surgical Sciences (NDS), presenting the research project 'Combined physiological and biochemical approach for the prediction of abdominal aortic aneurysm growth in humans' conducted through the OxAAA study.

Blog posts

Lights, camera, action! My journey into video production

Dr Hannah McGivern provides a 'behind-the-scenes' account of her experience producing the video 'Journey of a QUOD Sample: Donating to Transplant Research', supported by the funds from the University of Oxford Public Engagement with Research (PER) Seed Fund.

Mentoring in practice

NDS has launched a new, interdepartmental mentoring scheme called RECOGNISE. In this podcast, Gemma Horbatowski (HR Advisor) interviews Monica Dolton (Programme Manager and Research Project Manager) about her experiences of mentor-mentee relationships.

Wrap up of 2021

After a brilliant year of hard work and dedication, the SITU team has done some reflection on 2021, focusing on key events, trial progression, and more. Read on to discover how the year 2021 went for the SITU team...